Convener of Active Medical Product Surveillance Discussion (U13), 30097-30098 [E9-14904]
Download as PDF
30097
Federal Register / Vol. 74, No. 120 / Wednesday, June 24, 2009 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(in hours)
Total burden
(in hours)
Respondents
Form name
Continuous Miner Operator ..............
Foreman ............................................
Maintenance Shift Worker ................
Mobile Bridge Operator ....................
Roof Bolter Operator ........................
Scoop Operator ................................
Shuttle Car Operator ........................
Mechanic ...........................................
Beltman .............................................
Continuous Miner Operator Form ....
Foreman Form ..................................
Maintenance Shift Worker Form ......
Mobile Bridge Operator Form ..........
Roof Bolter Operator Form ..............
Scoop Operator Form ......................
Shuttle Car Operator Form ..............
Mechanic Form .................................
Beltman Form ...................................
5
5
10
10
14
6
6
6
2
1
1
1
1
1
1
1
1
1
10/60
10/60
10/60
10/60
10/60
10/60
10/60
10/60
10/60
1
1
2
2
2
1
1
1
0.5
Total ...........................................
...........................................................
........................
........................
........................
12
Dated: June 11, 2009.
Maryam I. Daneshvar,
Acting Reports Clearance Officer, Centers for
Disease Control and Prevention.
[FR Doc. E9–14834 Filed 6–23–09; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0275]
Convener of Active Medical Product
Surveillance Discussion (U13)
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of grant funds for the
support of a neutral, independent
institution and/or organization that
proposes appropriate methods and
processes for convening a broad range of
stakeholders with relevant expertise to
manage and support conferences and
meetings. The focus of the conferences
and meetings is to explore and address
methodological, data development,
technical, and communication issues
related to active medical product
surveillance. The awardee would be
expected to synthesize, summarize, and
communicate findings from these
conferences and meetings to a broad
range of organizations and individuals
who have the capability to use the
information to further develop and
create active medical product
surveillance methods and systems.
DATES: The application due date is July
15, 2009. The earliest start date is in
September 2009.
FOR FURTHER INFORMATION AND
ADDITIONAL REQUIREMENTS CONTACT:
Programmatic/Peer Review Contact:
VerDate Nov<24>2008
16:46 Jun 23, 2009
Jkt 217001
Melissa Robb, Office of Critical Path
Programs, Office of the
Commissioner, Food and Drug
Administration, 5600 Fishers Lane,
rm. 14B–45, Rockville, MD 20857,
301–827–1516, e-mail:
melissa.robb@fda.hhs.gov.
Financial or Grants Management
Contact: Gladys M. Bohler, Office of
Acquisitions and Grant Services,
Food and Drug Administration,
5630 Fishers Lane, rm. 2105,
Rockville, MD 20857, 301–827–
7168, FAX: 301–827–7101, e-mail:
gladys.bohler@fda.hhs.gov.
For more information on this funding
opportunity announcement (FOA) and
to obtain detailed requirements, please
refer to the full FOA located at https://
www.fda.gov/Safety/FDAsSentinel
Initiative/ucm149345.htm.
SUPPLEMENTARY INFORMATION:
I. Funding Opportunity Description
Request for Applications (RFA) Number:
RFA–FD09–012
Catalog of Federal Domestic Assistance
Number: 93.103
A. Background
In 2007, Congress enacted the Food
and Drug Administration Amendments
Act of 2007 (FDAAA). Section 905 of
this statute calls for the Secretary of
Health and Human Services (the
Secretary) to develop methods to obtain
access to disparate data sources and to
establish an active postmarket risk
identification and analysis system that
links and analyzes safety data from
multiple sources. The law sets a goal of
access to data from 25 million patients
by July 1, 2010, and 100 million patients
by July 1, 2012. The law also requires
FDA to work closely with partners from
public, academic, and private entities.
In May 2008, the Secretary and the
Commissioner of Food and Drugs
announced the launch of the Sentinel
Initiative, a long-term effort to create a
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
national electronic system for
monitoring regulated product safety.
Once implemented, the Sentinel System
is intended to augment FDA’s existing
postmarket (primarily passive) safety
surveillance systems and to enable FDA
to actively gather information about the
postmarket safety and performance of its
regulated products. FDA views its
Sentinel Initiative as a mechanism
through which some of the requirements
mandated in FDAAA can be carried out.
As currently envisioned, the Sentinel
System will enable FDA to capitalize on
the capabilities of multiple, existing
automated healthcare data systems (e.g.
electronic health record systems,
administrative claims databases,
registries). The Sentinel System will
enable queries of disparate data sources
quickly and securely for relevant
regulated product safety information.
Data will continue to be managed by its
owners, and only data of organizations
who agree to participate in this system
will be involved. FDA questions would
be sent to appropriate, participating data
holders, who would, in accordance with
existing privacy and security safeguards,
evaluate their data and send results
summaries to FDA for review.
Following announcement of the
Sentinel Initiative in May 2008, FDA’s
first step has been to create a broad
public forum for discussion of issues
related to developing and implementing
the Sentinel System. During 2008, FDA
sponsored a series of exploratory
meetings with a broad variety of
stakeholders to identify key issues that
will need to be addressed before,
during, and after implementation of the
Sentinel System. Key questions include,
for example, what level of collaboration
between public and private entities
would best ensure the success of the
initiative; how a possible governance
model could be identified and
developed; what kind of methods and
tools will be needed to facilitate the
E:\FR\FM\24JNN1.SGM
24JNN1
30098
Federal Register / Vol. 74, No. 120 / Wednesday, June 24, 2009 / Notices
development and sharing of highly
technical summary results derived from
automated healthcare data in disparate
systems; and what privacy and security
safeguards will be needed and how will
they be maintained.
B. Research Objectives
These initial discussions have focused
on many of the policy and procedural
needs of developing the Sentinel
System. However, to proceed, additional
meetings and working groups need to be
formed to explore in greater depth the
science of safety needed to support this
initiative, as well as methods for
communicating about the information
learned from the system. Topics to be
addressed include specific topics,
issues, and questions related to the
development of active medical product
surveillance methodologies and tools.
Subsequently, the information from
these meetings and working groups
must be described, managed, and made
available to the public using a
transparent and open approach.
C. Eligibility Information
The following organizations/
institutions are eligible to apply: Nonprofit organizations.
Foreign institutions are not eligible to
apply for conference grant support. An
international conference can be
supported through the U.S.
representative organization of an
established international scientific or
professional society.
II. Award Information/Funds Available
A. Award Amount
FDA anticipates providing up to
$600,000 (direct cost only) during fiscal
year (FY) 2009 to support efforts
outlined in this FOA. One award will be
made.
This Cooperative Agreement ensures
substantial FDA involvement in this
program and will include, but not be
limited to, co-development of the
meeting(s) priorities and agendas and
providing feedback on reports and
publications related to meeting
proceedings on identified topics.
B. Length of Support
Subject to the availability of Federal
funds and successful performance, and
if the FOA stated objectives are met, an
additional 4 years of support up to
$600,000 (direct and indirect costs
combined) per year may be available.
III. Electronic Application,
Registration, and Submission
Only electronic applications will be
accepted. To submit an electronic
application in response to this FOA,
VerDate Nov<24>2008
16:46 Jun 23, 2009
Jkt 217001
applicants should first review the full
announcement located at https://
www.fda.gov/Safety/FDAsSentinel
Initiative/ucm149345.htm.
For all electronically submitted
applications, the following steps are
required.
• Step 1: Obtain a Dun and Bradstreet
(DUNS) Number
• Step 2: Register With Central
Contractor Registration
• Step 3: Obtain Username &
Password
• Step 4: Authorized Organization
Representative (AOR) Authorization
• Step 5: Track AOR Status
• Step 6: Register With Electronic
Research Administration (eRA)
Commons
Steps 1 through 5, in detail, can be
found at https://www07.grants.gov/
applicants/organization_registration.jsp.
Step 6, in detail, can be found at https://
commons.era.nih.gov/commons/
registration/registrationInstructions.jsp.
After you have followed these steps,
submit electronic applications to https://
www.grants.gov.
Dated: June 19, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E9–14904 Filed 6–23–09; 8:45 am]
BILLING CODE 4160–01–S
the scientific and technical merit of grant and
cooperative agreement applications received
from academic institutions and other public
and private profit and nonprofit
organizations, including State and local
government agencies, to conduct specific
injury research that focuses on prevention
and control.
Matters To Be Discussed: The meeting will
include the review, discussion, and
evaluation of individual research cooperative
agreement applications submitted in
response to Fiscal Year 2009 Requests for
Applications related to the following
individual research announcement: RFA–
CD–09–001 ‘‘Translating Research to Protect
Health through Health Promotion,
Prevention, and Preparedness (R18)’’ for the
National Center for Injury Prevention and
Control (NCIPC) applications.
Agenda items are subject to change as
priorities dictate.
Contact Person for More Information: Jane
Suen, Dr.P.H., M.S., NCIPC, CDC, 4770
Buford Highway, NE., Mailstop F–62,
Atlanta, Georgia 30341. Telephone: (770)
488–4281.
The Director, Management Analysis and
Services Office has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Dated: June 12, 2009.
Elaine L. Baker,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E9–14740 Filed 6–23–09; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4163–18–P
Centers for Disease Control and
Prevention
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Center for Injury Prevention
and Control Initial Review Group
(NCIPC IRG)
Health Resources and Services
Administration
Public Health Service Act, Section
330(e)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC),
announces the following meeting of the
aforementioned committee:
AGENCY: Health Resources and Services
Administration (HRSA), HHS.
ACTION: Notification of Exception to
Competition—Replacement Grant.
Times and Date: 9 a.m.–9:30 a.m., July 14,
2009(Open) 9:30 a.m.–5 p.m., July 14,
2009(Closed) 9 a.m.–5 p.m., July 15,
2009(Closed)
Place: Doubletree Hotel Atlanta-Buckhead,
3342 Peachtree Road, Atlanta, GA 30326,
Telephone: (404) 231–1234.
Status: Portions of the meetings will be
closed to the public in accordance with
provisions set forth in Section 552b(c)(4) and
(6), Title 5, U.S.C., and the Determination of
the Director, Management Analysis and
Services Office, CDC, pursuant to Section
10(d) of Public Law 92–463.
Purpose: This group is charged with
providing advice and guidance to the
Secretary, Department of Health and Human
Services, and the Director, CDC, concerning
SUMMARY: The Health Resources and
Services Administration (HRSA) is
issuing a non-competitive award to the
Community Health Clinics of Northeast
Texas (CHCNET) to avoid disruption
and continue providing primary health
care services to the population of Smith
County, Texas, as an independent
organization from the Northeast Texas
Public Health District (NETPHD).
SUPPLEMENTARY INFORMATION:
Intended Recipient of the Award:
Community Health Clinics of Northeast
Texas.
Amount of the Award: $326,308.00
(initial seven-month supplement,
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
E:\FR\FM\24JNN1.SGM
24JNN1
Agencies
[Federal Register Volume 74, Number 120 (Wednesday, June 24, 2009)]
[Notices]
[Pages 30097-30098]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-14904]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2009-N-0275]
Convener of Active Medical Product Surveillance Discussion (U13)
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
availability of grant funds for the support of a neutral, independent
institution and/or organization that proposes appropriate methods and
processes for convening a broad range of stakeholders with relevant
expertise to manage and support conferences and meetings. The focus of
the conferences and meetings is to explore and address methodological,
data development, technical, and communication issues related to active
medical product surveillance. The awardee would be expected to
synthesize, summarize, and communicate findings from these conferences
and meetings to a broad range of organizations and individuals who have
the capability to use the information to further develop and create
active medical product surveillance methods and systems.
DATES: The application due date is July 15, 2009. The earliest start
date is in September 2009.
FOR FURTHER INFORMATION AND ADDITIONAL REQUIREMENTS CONTACT:
Programmatic/Peer Review Contact: Melissa Robb, Office of Critical
Path Programs, Office of the Commissioner, Food and Drug
Administration, 5600 Fishers Lane, rm. 14B-45, Rockville, MD 20857,
301-827-1516, e-mail: melissa.robb@fda.hhs.gov.
Financial or Grants Management Contact: Gladys M. Bohler, Office of
Acquisitions and Grant Services, Food and Drug Administration, 5630
Fishers Lane, rm. 2105, Rockville, MD 20857, 301-827-7168, FAX: 301-
827-7101, e-mail: gladys.bohler@fda.hhs.gov.
For more information on this funding opportunity announcement (FOA)
and to obtain detailed requirements, please refer to the full FOA
located at https://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149345.htm.
SUPPLEMENTARY INFORMATION:
I. Funding Opportunity Description
Request for Applications (RFA) Number: RFA-FD09-012
Catalog of Federal Domestic Assistance Number: 93.103
A. Background
In 2007, Congress enacted the Food and Drug Administration
Amendments Act of 2007 (FDAAA). Section 905 of this statute calls for
the Secretary of Health and Human Services (the Secretary) to develop
methods to obtain access to disparate data sources and to establish an
active postmarket risk identification and analysis system that links
and analyzes safety data from multiple sources. The law sets a goal of
access to data from 25 million patients by July 1, 2010, and 100
million patients by July 1, 2012. The law also requires FDA to work
closely with partners from public, academic, and private entities.
In May 2008, the Secretary and the Commissioner of Food and Drugs
announced the launch of the Sentinel Initiative, a long-term effort to
create a national electronic system for monitoring regulated product
safety. Once implemented, the Sentinel System is intended to augment
FDA's existing postmarket (primarily passive) safety surveillance
systems and to enable FDA to actively gather information about the
postmarket safety and performance of its regulated products. FDA views
its Sentinel Initiative as a mechanism through which some of the
requirements mandated in FDAAA can be carried out.
As currently envisioned, the Sentinel System will enable FDA to
capitalize on the capabilities of multiple, existing automated
healthcare data systems (e.g. electronic health record systems,
administrative claims databases, registries). The Sentinel System will
enable queries of disparate data sources quickly and securely for
relevant regulated product safety information. Data will continue to be
managed by its owners, and only data of organizations who agree to
participate in this system will be involved. FDA questions would be
sent to appropriate, participating data holders, who would, in
accordance with existing privacy and security safeguards, evaluate
their data and send results summaries to FDA for review.
Following announcement of the Sentinel Initiative in May 2008,
FDA's first step has been to create a broad public forum for discussion
of issues related to developing and implementing the Sentinel System.
During 2008, FDA sponsored a series of exploratory meetings with a
broad variety of stakeholders to identify key issues that will need to
be addressed before, during, and after implementation of the Sentinel
System. Key questions include, for example, what level of collaboration
between public and private entities would best ensure the success of
the initiative; how a possible governance model could be identified and
developed; what kind of methods and tools will be needed to facilitate
the
[[Page 30098]]
development and sharing of highly technical summary results derived
from automated healthcare data in disparate systems; and what privacy
and security safeguards will be needed and how will they be maintained.
B. Research Objectives
These initial discussions have focused on many of the policy and
procedural needs of developing the Sentinel System. However, to
proceed, additional meetings and working groups need to be formed to
explore in greater depth the science of safety needed to support this
initiative, as well as methods for communicating about the information
learned from the system. Topics to be addressed include specific
topics, issues, and questions related to the development of active
medical product surveillance methodologies and tools. Subsequently, the
information from these meetings and working groups must be described,
managed, and made available to the public using a transparent and open
approach.
C. Eligibility Information
The following organizations/institutions are eligible to apply:
Non-profit organizations.
Foreign institutions are not eligible to apply for conference grant
support. An international conference can be supported through the U.S.
representative organization of an established international scientific
or professional society.
II. Award Information/Funds Available
A. Award Amount
FDA anticipates providing up to $600,000 (direct cost only) during
fiscal year (FY) 2009 to support efforts outlined in this FOA. One
award will be made.
This Cooperative Agreement ensures substantial FDA involvement in
this program and will include, but not be limited to, co-development of
the meeting(s) priorities and agendas and providing feedback on reports
and publications related to meeting proceedings on identified topics.
B. Length of Support
Subject to the availability of Federal funds and successful
performance, and if the FOA stated objectives are met, an additional 4
years of support up to $600,000 (direct and indirect costs combined)
per year may be available.
III. Electronic Application, Registration, and Submission
Only electronic applications will be accepted. To submit an
electronic application in response to this FOA, applicants should first
review the full announcement located at https://www.fda.gov/Safety/FDAsSentinelInitiative/ucm149345.htm.
For all electronically submitted applications, the following steps
are required.
Step 1: Obtain a Dun and Bradstreet (DUNS) Number
Step 2: Register With Central Contractor Registration
Step 3: Obtain Username & Password
Step 4: Authorized Organization Representative (AOR)
Authorization
Step 5: Track AOR Status
Step 6: Register With Electronic Research Administration
(eRA) Commons
Steps 1 through 5, in detail, can be found at https://www07.grants.gov/applicants/organization_registration.jsp. Step 6, in
detail, can be found at https://commons.era.nih.gov/commons/registration/registrationInstructions.jsp. After you have followed
these steps, submit electronic applications to https://www.grants.gov.
Dated: June 19, 2009.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E9-14904 Filed 6-23-09; 8:45 am]
BILLING CODE 4160-01-S